Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
August 23, 2024 12:00 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 23. august 2024 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
August 23, 2024 12:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, August 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding...
Bavarian Nordic Announces First Half 2024 Results
August 22, 2024 01:45 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, August 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2024 and released its financial...
Bavarian Nordic Announces First Half 2024 Results
August 22, 2024 01:45 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, August 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first half of 2024 and released its financial...
Bavarian Nordic modtager kontrakt på 440,000 doser vedrørende levering af koppe- og mpoxvacciner til et europæisk land
August 21, 2024 13:30 ET
|
Bavarian Nordic A/S
Ordren var ventet som en del af de økonomiske forventninger til 2024 og har ingen indvirkning på den tilbageværende produktionskapacitet for selskabets koppe- og mpoxvaccine i 2024/2025. KØBENHAVN,...
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
August 21, 2024 13:30 ET
|
Bavarian Nordic A/S
The order was anticipated as part of the 2024 guidance and has no impact on the remaining 2024/25 capacity for the Company’s smallpox and mpox vaccine. COPENHAGEN, Denmark, August 21, 2024 – Bavarian...
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
August 17, 2024 07:26 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of vaccines to tackle the current mpox outbreak that the Africa Centers for...
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders
August 17, 2024 07:26 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of vaccines to tackle the current mpox outbreak that the Africa Centers for...
Bavarian Nordic indsender data til det Europæiske Lægemiddelagentur til udvidelse af godkendelsen af mpox- og koppevaccinen til at omfatte teenagere
August 16, 2024 01:30 ET
|
Bavarian Nordic A/S
Midlertidige resultater fra klinisk forsøg viser sammenlignelige immunresponser hos teenagere og voksne efter vaccination med mpox-/koppevaccine samt ensartet bivirkningsprofil, hvilket understøtter...
Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents
August 16, 2024 01:30 ET
|
Bavarian Nordic A/S
Interim results from clinical study show non-inferiority of immune responses from mpox/smallpox vaccination in adolescents and similar safety profile compared to adults, supporting the extension of...